EMA: Updated Q&A documents on Centralised Procedures
![Drug Master File Procedures in the EU, the US and Japan - Live Online Training](files/eca/userImages/training.img/Z-ECA-Drug-Master-File-Procedures-LOT.jpg)
Recommendation
17/18 September 2024
With updates on the CEP 2.0!
In January 2021, the European Medicines Agency (EMA) published on its website updated and revised versions of the "Questions & Answers (Q&A)" documents related to centralised procedures. These Q&As are intended to provide guidance and support for marketing authorisation holders and applicants of centralised procedures and provide answers to potential questions before and during the submission.
Generics
For applicants of centralised procedures for generic or hybrid medicinal products, the explanations given in the Q&A paper "European Medicines Agency procedural advice for users of the centralised procedure for generic/hybrid applications" are of particular interest. The updated version includes an amendment to paragraph 2.1., which refers to the legal basis to be fulfilled.
Pre-authorisation advice
Questions related to issues before and during the submission of an application for a centralised procedure are listed and answered in the document "European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure", which was last revised in October 2020. Amendments were made mainly to the subjects "paediatric use marketing authoristaion (PUMA)" (paragraph 1.7., paragraph 2.1.2.3. and paragraph 3.2.1.) and "dossier preparation, in particular proposed product name" (paragraph 3.1.1.).
Post-authorisation advice
The Q&A document "European Medicines Agency post-authorisation procedural advice for users of the centralised procedure", which was also updated in October 2020, was revised and published in its latest version on the EMA website as well. This questions and answers catalogue handles post-authorisation topics. It includes, for example, explanations on how to deal with variations or marketing authorisation renewals. The revised version mentions updates in paragraphs 3.8., 4.3., 14.2. and 16.11.
The new versions of the "Q&A" documents for centralised procedures can be found here:
- Generic and hybrid applications
- Pre-authorisation topics
- Post-authorisation topics
Related GMP News
17.07.2024EMA: Q&A document for "Centralised Procedures" updated again
16.07.2024CMDh/HMA: New Update of the Q&A List on Variations
18.06.2024EDQM: New Guideline for sterile Substances published for Comment
18.06.2024EMA updates IRIS Guide
02.05.2024EDQM: Updated Information on the Quality Overall Summary (Module 2)
02.05.2024EDQM: Manufacturing Sites in CEP 2.0?